- Somatostatin Analogues
- Octreotide
- Lanreotide
- Pasireotide
- Chemotherapeutics
- Fluorouracil (5-FU)
- Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
- Streptozocin
- Temozolomide (Temodar)
- Capecitabine (Xeloda)
- Dacarbazine (DTIC)
- Oxaliplatin (Eloxatin)
- Targeted Therapeutics
- Sunitinib
- Everolimus
- Others
Neuroendocrine Tumors Therapeutics Market size was valued at USD 1.6 billion in 2023 and is poised to grow at a significant CAGR of 8.2% from 2024-2030. Neuroendocrine tumors (NET) are abnormal growths that begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arise from several neuroendocrine cells whose normal functions are to serve at the neuroendocrine interface.
Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands. The neuroendocrine tumor therapeutics market is expected to grow owing to an increase in initiatives taken by various international organizations like the American Association for Cancer Research and the World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided a $250,000 fund for the Prevention of neuroendocrine tumors. The rise in health care expenditure and an increase in the prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive the neuroendocrine tumor therapeutics market growth. Though the market is expected to witness healthy growth, the lack of skilled healthcare professionals and lower adoption of advanced treatment technologies in developing economies are key restraints for the neuroendocrine tumors market.
Global Neuroendocrine Tumors Therapeutics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8.2%
Largest Market
North-America
Fastest Growing Market
Asia Pacific
Neuroendocrine Tumors Therapeutics Market Dynamics
The neuroendocrine tumors treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumors by treating with various medications are expected to have a positive impact on neuroendocrine tumors market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.
North-America Got Significant Share of
Neuroendocrine Tumors Therapeutics Market Regional Analysis
Based on the geographical regions, global neuroendocrine tumors therapeutics market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumors therapeuticsare based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America neuroendocrine tumors therapeutics market. Europe is the second largest market for neuroendocrine tumors therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Neuroendocrine Tumors Therapeutics Market Segmentation
By Drug Class
By Indication
- Lung NET
- Others NET
- Gastrointestinal NET
- Pancreatic NET
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Frequently Asked Questions
The neuroendocrine tumors therapeutics market size was valued at USD 1.6 billion in 2023
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The neuroendocrine tumors therapeutics market key players are Pfizer Inc., (U.S) Eli Lilly & Company (U.S.) Novartis AG (Switzerland) F. Hoffmann-La Roche Ltd.(Switzerland) Ipsen (France) Amgen, Inc. (U.S.) Teva Pharmaceuticals, Ltd. (Israel) Bristol-Myers Squibb (U.S.)
| 1.Executive Summary |
| 2.Global Neuroendocrine Tumors Therapeutics Market Introduction |
| 2.1.Global Neuroendocrine Tumors Therapeutics Market - Taxonomy |
| 2.2.Global Neuroendocrine Tumors Therapeutics Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Indication |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Neuroendocrine Tumors Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Neuroendocrine Tumors Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Neuroendocrine Tumors Therapeutics Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Somatostatin Analogues |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Chemotherapeutics |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Targeted Therapeutics |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Neuroendocrine Tumors Therapeutics Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Lung NET |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Others NET |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Gastrointestinal NET |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Pancreatic NET |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Neuroendocrine Tumors Therapeutics Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Neuroendocrine Tumors Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Somatostatin Analogues |
| 9.1.2.Chemotherapeutics |
| 9.1.3.Targeted Therapeutics |
| 9.1.4.Others |
| 9.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Lung NET |
| 9.2.2.Others NET |
| 9.2.3.Gastrointestinal NET |
| 9.2.4.Pancreatic NET |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Somatostatin Analogues |
| 10.1.2.Chemotherapeutics |
| 10.1.3.Targeted Therapeutics |
| 10.1.4.Others |
| 10.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Lung NET |
| 10.2.2.Others NET |
| 10.2.3.Gastrointestinal NET |
| 10.2.4.Pancreatic NET |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Somatostatin Analogues |
| 11.1.2.Chemotherapeutics |
| 11.1.3.Targeted Therapeutics |
| 11.1.4.Others |
| 11.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Lung NET |
| 11.2.2.Others NET |
| 11.2.3.Gastrointestinal NET |
| 11.2.4.Pancreatic NET |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Somatostatin Analogues |
| 12.1.2.Chemotherapeutics |
| 12.1.3.Targeted Therapeutics |
| 12.1.4.Others |
| 12.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Lung NET |
| 12.2.2.Others NET |
| 12.2.3.Gastrointestinal NET |
| 12.2.4.Pancreatic NET |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Neuroendocrine Tumors Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Somatostatin Analogues |
| 13.1.2.Chemotherapeutics |
| 13.1.3.Targeted Therapeutics |
| 13.1.4.Others |
| 13.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Lung NET |
| 13.2.2.Others NET |
| 13.2.3.Gastrointestinal NET |
| 13.2.4.Pancreatic NET |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Pfizer Inc., (U.S) |
| 14.2.2.Eli Lilly & Company (U.S.) |
| 14.2.3.Novartis AG (Switzerland) |
| 14.2.4.F. Hoffmann-La Roche Ltd.(Switzerland) |
| 14.2.5.Ipsen (France) |
| 14.2.6.Amgen, Inc. (U.S.) |
| 14.2.7.Teva Pharmaceuticals, Ltd. (Israel) |
| 14.2.8.Bristol-Myers Squibb (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Pfizer Inc., (U.S)
- Eli Lilly & Company (U.S.)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd.(Switzerland)
- Ipsen (France)
- Amgen, Inc. (U.S.)
- Teva Pharmaceuticals, Ltd. (Israel)
- Bristol-Myers Squibb (U.S.)